Skip to main content
HR 7121 117th Congress House Health Asia Business expenses China Drug safety, medical device, and laboratory regulation Government information and archives Health care costs and insurance Health programs administration and funding Health technology, devices, supplies Income tax deductions Manufacturing Military medicine Military procurement, research, weapons development Prescription drugs Public contracts and procurement Trade restrictions Veterans' medical care

Protecting our Pharmaceutical Supply Chain from China Act of 2022

Introduced: March 17, 2022 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 28, 2022
Referred to the Subcommittee on Health.
Mar 18, 2022
Referred to the Subcommittee on Health.
Mar 17, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 17, 2022
Introduced in House
 Plain-English summary Congressional Research Service

Protecting our Pharmaceutical Supply Chain from China Act of 2022

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.

The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.

Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.

The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.

What's happening now March 28, 2022

Referred to the Subcommittee on Health.

 Committees of jurisdiction 6
 Cosponsors 5
All 5 Republican 5